AABB is the voice of the blood and cellular therapies community before the Food and Drug Administration and FDA advisory committees, such as the Blood Products Advisory Committee and Cellular, Tissue, and Gene Therapies Advisory Committee. The Association engages stakeholders within AABB's membership and the broader community to develop materials that provide FDA with the community’s position on draft guidances, proposed regulations and policies, and research priorities. These AABB-led efforts create an important dialogue with federal regulators that helps promote a strong and safe supply of blood and cells.
New Biotherapies Approved in the EU, UK and US
December 01, 2025
FDA Investigating Patient Death Following Recombinant ADAMTS13 Therapy
November 25, 2025
FDA Leaders Propose New Regulatory Pathway for Bespoke Therapies
November 19, 2025
4550 Montgomery Avenue
Suite 700, North Tower
Bethesda, MD 20814
301.907.6977
